Viyash Scientific Ltd

Viyash Scientific Employee Stock Options

Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.

Viyash Scientific Board Meeting Date

Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.

Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr

Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.

Value

₹3.80 Cr

Viyash Scientific Management Change

Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.

Viyash Scientific Capital Structure Change

White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.

Viyash Scientific Other Announcement

Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.

Viyash Scientific Employee Stock Options

Viyash Scientific allotted 1,35,880 ESOP shares at exercise prices of Rs. 86 and Rs. 101. The allotment reflects employee stock option exercises under two active schemes.

Viyash Scientific Acquisition Worth ₹193.4 Cr

Viyash Scientific's subsidiary completed the acquisition of BioForLife Italia s.r.l. for a total consideration of Rs.193.41 Crore. This transaction was previously announced in June.

Value

₹193.4 Cr

Viyash Scientific Acquisition Worth ₹18.33 Cr

Viyash Scientific's subsidiary completed the acquisition of Italy-based BioForLife Italia S.r.l. for a total consideration of approximately EUR 16.98 million.

Value

₹18.33 Cr

Viyash Scientific Employee Stock Options

Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.

Viyash Scientific Merger & Restructuring

Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.

Viyash Scientific Acquisition

Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.

Viyash Scientific Employee Stock Options

Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.

Viyash Scientific Promoter Selling

Promoters CA Harbor Investments and CA Hull Investments sold a combined 5.03 crore equity shares of Viyash Scientific Limited through open market transactions.

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.

Call

Guides 18% growth

Viyash Scientific Earnings Call Transcript: Key Takeaways

Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.

Call

Guides 18% growth

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.